BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 21184265)

  • 1. Reproductive history and risk of three breast cancer subtypes defined by three biomarkers.
    Phipps AI; Buist DS; Malone KE; Barlow WE; Porter PL; Kerlikowske K; Li CI
    Cancer Causes Control; 2011 Mar; 22(3):399-405. PubMed ID: 21184265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reproductive characteristics, menopausal status, race and ethnicity, and risk of breast cancer subtypes defined by ER, PR and HER2 status: the Breast Cancer Etiology in Minorities study.
    John EM; Koo J; Phipps AI; Longacre TA; Kurian AW; Ingles SA; Wu AH; Hines LM
    Breast Cancer Res; 2024 May; 26(1):88. PubMed ID: 38822357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parity, hormones and breast cancer subtypes - results from a large nested case-control study in a national screening program.
    Ellingjord-Dale M; Vos L; Tretli S; Hofvind S; Dos-Santos-Silva I; Ursin G
    Breast Cancer Res; 2017 Jan; 19(1):10. PubMed ID: 28114999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies.
    Yang XR; Chang-Claude J; Goode EL; Couch FJ; Nevanlinna H; Milne RL; Gaudet M; Schmidt MK; Broeks A; Cox A; Fasching PA; Hein R; Spurdle AB; Blows F; Driver K; Flesch-Janys D; Heinz J; Sinn P; Vrieling A; Heikkinen T; Aittomäki K; Heikkilä P; Blomqvist C; Lissowska J; Peplonska B; Chanock S; Figueroa J; Brinton L; Hall P; Czene K; Humphreys K; Darabi H; Liu J; Van 't Veer LJ; van Leeuwen FE; Andrulis IL; Glendon G; Knight JA; Mulligan AM; O'Malley FP; Weerasooriya N; John EM; Beckmann MW; Hartmann A; Weihbrecht SB; Wachter DL; Jud SM; Loehberg CR; Baglietto L; English DR; Giles GG; McLean CA; Severi G; Lambrechts D; Vandorpe T; Weltens C; Paridaens R; Smeets A; Neven P; Wildiers H; Wang X; Olson JE; Cafourek V; Fredericksen Z; Kosel M; Vachon C; Cramp HE; Connley D; Cross SS; Balasubramanian SP; Reed MW; Dörk T; Bremer M; Meyer A; Karstens JH; Ay A; Park-Simon TW; Hillemanns P; Arias Pérez JI; Menéndez Rodríguez P; Zamora P; Benítez J; Ko YD; Fischer HP; Hamann U; Pesch B; Brüning T; Justenhoven C; Brauch H; Eccles DM; Tapper WJ; Gerty SM; Sawyer EJ; Tomlinson IP; Jones A; Kerin M; Miller N; McInerney N; Anton-Culver H; Ziogas A; Shen CY; Hsiung CN; Wu PE; Yang SL; Yu JC; Chen ST; Hsu GC; Haiman CA; Henderson BE; Le Marchand L; Kolonel LN; Lindblom A; Margolin S; Jakubowska A; Lubiński J; Huzarski T; Byrski T; Górski B; Gronwald J; Hooning MJ; Hollestelle A; van den Ouweland AM; Jager A; Kriege M; Tilanus-Linthorst MM; Collée M; Wang-Gohrke S; Pylkäs K; Jukkola-Vuorinen A; Mononen K; Grip M; Hirvikoski P; Winqvist R; Mannermaa A; Kosma VM; Kauppinen J; Kataja V; Auvinen P; Soini Y; Sironen R; Bojesen SE; Ørsted DD; Kaur-Knudsen D; Flyger H; Nordestgaard BG; Holland H; Chenevix-Trench G; Manoukian S; Barile M; Radice P; Hankinson SE; Hunter DJ; Tamimi R; Sangrajrang S; Brennan P; McKay J; Odefrey F; Gaborieau V; Devilee P; Huijts PE; Tollenaar RA; Seynaeve C; Dite GS; Apicella C; Hopper JL; Hammet F; Tsimiklis H; Smith LD; Southey MC; Humphreys MK; Easton D; Pharoah P; Sherman ME; Garcia-Closas M
    J Natl Cancer Inst; 2011 Feb; 103(3):250-63. PubMed ID: 21191117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer.
    Phipps AI; Chlebowski RT; Prentice R; McTiernan A; Wactawski-Wende J; Kuller LH; Adams-Campbell LL; Lane D; Stefanick ML; Vitolins M; Kabat GC; Rohan TE; Li CI
    J Natl Cancer Inst; 2011 Mar; 103(6):470-7. PubMed ID: 21346227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship of established risk factors with breast cancer subtypes.
    McCarthy AM; Friebel-Klingner T; Ehsan S; He W; Welch M; Chen J; Kontos D; Domchek SM; Conant EF; Semine A; Hughes K; Bardia A; Lehman C; Armstrong K
    Cancer Med; 2021 Sep; 10(18):6456-6467. PubMed ID: 34464510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of four biomarkers to evaluate the risk of breast cancer subtypes in the women's contraceptive and reproductive experiences study.
    Ma H; Wang Y; Sullivan-Halley J; Weiss L; Marchbanks PA; Spirtas R; Ursin G; Burkman RT; Simon MS; Malone KE; Strom BL; McDonald JA; Press MF; Bernstein L
    Cancer Res; 2010 Jan; 70(2):575-87. PubMed ID: 20068186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A case-control study of reproductive factors associated with subtypes of breast cancer in Northeast China.
    Xing P; Li J; Jin F
    Med Oncol; 2010 Sep; 27(3):926-31. PubMed ID: 19771534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
    Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
    BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breast Cancer Outcomes as Defined by the Estrogen Receptor, Progesterone Receptor, and Human Growth Factor Receptor-2 in a Multi-ethnic Asian Country.
    Subramaniam S; Bhoo-Pathy N; Taib NA; Tan GH; See MH; Jamaris S; Ho GF; Looi LM; Yip CH
    World J Surg; 2015 Oct; 39(10):2450-8. PubMed ID: 26138872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reproductive factors and subtypes of breast cancer defined by estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2: a register-based study from Korea.
    Lee JS; Oh M; ;
    Clin Breast Cancer; 2014 Dec; 14(6):426-34. PubMed ID: 25034438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disparities in the risk of the ER/PR/HER2 breast cancer subtypes among Asian Americans in California.
    Parise C; Caggiano V
    Cancer Epidemiol; 2014 Oct; 38(5):556-62. PubMed ID: 25172158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reproductive behaviors and risk of developing breast cancer according to tumor subtype: A systematic review and meta-analysis of epidemiological studies.
    Lambertini M; Santoro L; Del Mastro L; Nguyen B; Livraghi L; Ugolini D; Peccatori FA; Azim HA
    Cancer Treat Rev; 2016 Sep; 49():65-76. PubMed ID: 27529149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reproductive history differs by molecular subtypes of breast cancer among women aged ≤ 50 years in Scotland diagnosed 2009-2016: a cross-sectional study.
    Chitkara A; Mesa-Eguiagaray I; Wild SH; Hall PS; Cameron DA; Sims AH; Figueroa JD
    Breast Cancer Res Treat; 2022 Nov; 196(2):379-387. PubMed ID: 36116093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Family history of breast cancer in first-degree relatives and triple-negative breast cancer risk.
    Phipps AI; Buist DS; Malone KE; Barlow WE; Porter PL; Kerlikowske K; Li CI
    Breast Cancer Res Treat; 2011 Apr; 126(3):671-8. PubMed ID: 20814817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reproductive Factors and Risk of Luminal, HER2-Overexpressing, and Triple-Negative Breast Cancer Among Multiethnic Women.
    Chen L; Li CI; Tang MT; Porter P; Hill DA; Wiggins CL; Cook LS
    Cancer Epidemiol Biomarkers Prev; 2016 Sep; 25(9):1297-304. PubMed ID: 27307466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estrogen receptor, progesterone receptor, and HER2-neu expression in first primary breast cancers and risk of second primary contralateral breast cancer.
    Saltzman BS; Malone KE; McDougall JA; Daling JR; Li CI
    Breast Cancer Res Treat; 2012 Oct; 135(3):849-55. PubMed ID: 22903686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breast Cancer Survival Analysis Based on Immunohistochemistry Subtypes (ER/PR/HER2): a Retrospective Cohort Study.
    Poorolajal J; Nafissi N; Akbari ME; Mahjub H; Esmailnasab N; Babaee E
    Arch Iran Med; 2016 Oct; 19(10):680-686. PubMed ID: 27743431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct ER and PR expression patterns significantly affect the clinical outcomes of early HER2-positive breast cancer: A real-world analysis of 871 patients treated with neoadjuvant therapy.
    Chen H; Gui X; Zhou Z; Su F; Gong C; Li S; Wu W; Rao N; Liu Q; Yao H
    Breast; 2024 Jun; 75():103733. PubMed ID: 38615482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hormone receptor and HER2 status in patients with breast cancer by races in southeastern Turkey.
    Kuzhan A; Adli M; Eryigit Alkis H; Caglayan D
    J BUON; 2013; 18(3):619-22. PubMed ID: 24065473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.